# US 2014/0213590 A1 · Certain dipeptidyl peptidase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0213590 A1
- Document ID: US20140213590A1
- Status: Published application
- Kind: A1
- Application number: 14/146,749
- Filed: 2014-01-03
- Published: 2014-07-31
- Earliest claimed: 2009-12-30
- Assignees: Fochon Pharma, Inc.
- Inventors: WEIBO WANG; TONGSHUANG LI
- Web page: https://patentgrep.com/patent/US20140213590A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are certain dipeptidyl peptidase inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from:
C1-10 alkyl,
C3-10 cycloalkyl,
C3-10 cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl,
aryl,
arylalkyl,
heteroaryl, and
heteroarylalkyl,
wherein alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R6a, and wherein aryl and heteroaryl are each unsubstituted or independently substituted with at least one substituent independently selected from R6b;
R2 is alkyl,
wherein each alkyl is unsubstituted or substituted with at least one substituent independently selected from R6a;
R3 is selected from:
hydrogen,
halogen,
hydroxyl,
C1-4 alkyl,
C2-4 alkenyl,
C2-4 alkynyl,
C3-7 cycloalkyl,
heterocyclyl,
C3-7 cycloalkylalkyl,
heterocyclylalkyl,
aryl,
heteroaryl,
arylalkyl, and
heteroarylalkyl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R6a, and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R6b;
R4 is selected from:
hydrogen, and
C1-4 alkyl,
wherein alkyl is unsubstituted or substituted with at least one substituent independently selected from R6a;
R5 is selected from:
hydrogen, and
C1-4 alkyl,
wherein alkyl is unsubstituted or substituted with at least one substituent independently selected from R6a;
or R4 and R5 together with the nitrogen to which they are attached form a heterocyclic ring;
each R6a is independently selected from:
—OR8,
—NR7S(O)mR8,
—NO2,
halogen,
—S(O)mR7,
—SR8,
—S(O)2OR7,
—OS(O)2R8,
—S(O)mNR7R8,
—NR7R8,
—O(CR9R10)nNR7R8,
—C(O)R7,
—CO2R6,
—CO2(CR9R10)nCONR7R8,
—OC(O)R7,
—CN,
—C(O)NR7R6,
—NR7C(O)R8,
—OC(O)NR7R8,
—NR7C(O)OR8,
—NR7C(O)NR7R8,
—CR7(N—OR8),
—CF2,
—CF3,
—OCF2, and
—OCF3,
each R6b is independently selected from:
R6a,
C1-10 alkyl,
aryl,
aryl-C1-4 alkyl,
heteroaryl, and
heteroaryl-C1-4 alkyl;
R7 and R8 are independently selected from:
hydrogen,
C1-10 alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
cycloalkyl,
cycloalkyl-C1-10 alkyl;
heterocyclyl,
heterocyclyl-C1-10 alkyl,
aryl,
heteroaryl,
aryl-C1-10 alkyl, and
heteroaryl-C1-10 alkyl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R6a, and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R6b; or
R7 and R8 together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and NR11,
each R7 and R8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent selected from R12;
R9 and R10 are independently selected from hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, heterocyclyl, heterocyclyl —C1-10 alkyl, aryl, heteroaryl,
aryl-C1-10 alkyl, and heteroaryl-C1-10 alkyl; or
R9 and R10 together with the carbon to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;
each R11 is independently selected from:
hydrogen,
C1-10 alkyl,
C3-8 cycloalkyl,
C3-8 cycloalkyl-C1-4 alkyl,
heterocyclyl,
heterocyclyl-C1-4 alkyl,
aryl,
aryl-C1-4 alkyl,
heteroaryl,
heteroaryl-C1-4 alkyl,
—S(O)mR7,
—C(O)R7,
—CO2R7,
—CO2(CR9R10)nCONR7R8, and
—C(O)NR7R8;
each R12 is independently selected from:
halogen,
C1-10 alkyl,
C3 cycloalkyl,
C3-8 cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl,
aryl,
aryl-C1-4 alkyl,
heteroaryl,
heteroaryl-C1-4 alkyl,
—OR7,
—NR7S(O)mR8,
—S(O)mR7,
—SR7,
—S(O)2OR7,
—OS(O)2R7,
—S(O)mNR7R8,
—NR7R8,
—O(CR9R10)nNR7R8,
—C(O)R7,
—CO2R8,
—CO2(CR9R10)nCONR7R8,
—OC(O)R7,
—CN,
—C(O)NR7R8,
—NR7C(O)R8,
—OC(O)NR7R8,
—NR7C(O)OR8,
—NR7C(O)NR7R8,
—CF2,
—CF3,
—OCF2, and
—OCF3;
L is —CR7R8—;
m is selected from 1 and 2; and
n is selected from 1, 2, and 3.

### Claim 19 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein L is —CR7R8, and at least one of R7 and R8 is hydrogen.

### Claim 20 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein L is —CH2.

### Claim 21 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.

### Claim 22 (depends on 18)

The compound of claim 18, and/or at least one pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with at least one substituent independently selected from R6b.

### Claim 23 (depends on 22)

The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein R1 phenyl optionally substituted with at least one substituent independently selected from R6b.

### Claim 24 (depends on 23)

The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl, optionally substituted with at least one substituent selected from halogen and cyano.

### Claim 25 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from 2-cyanophenyl, 2-chloro-5-fluorophenyl, 2-cyano-5-fluorophenyl, and 2-bromo-5-fluorophenyl.

### Claim 26 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen.

### Claim 27 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen.

### Claim 28 (depends on 18)

The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R5 is hydrogen.

### Claim 29 (depends on 18)

A pharmaceutical composition which comprises a compound of claim 18, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 30 (depends on 18)

A method of treating a condition responsive to inhibition of dipeptidyl peptidase-IV enzyme comprising administering to a patient in recognized need thereof an effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 18)

A method for treating a condition selected from insulin resistance, hyperglycemia, and type II diabetes comprising administering to a patient in recognized need thereof an effective amount of a compound of claim 18, or a pharmaceutically acceptable salt thereof.
